Uncertainty management in regulatory and health technology assessment decision-making on drugs : guidance of the HTAi-DIA Working Group
OBJECTIVES: Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface.
METHODS: Six online discussions among WG members (Dec 2021-Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions.
RESULTS: The WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: "unavailable," "inaccurate," "conflicting," "not understandable," "random variation," "information," "prediction," "impact," "risk," "relevance," "context," and "judgment." These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed.
CONCLUSIONS: The systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
International journal of technology assessment in health care - 39(2023), 1 vom: 16. Juni, Seite e40 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hogervorst, Milou Amber [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drugs |
|---|
| Anmerkungen: |
Date Completed 06.07.2023 Date Revised 06.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1017/S0266462323000375 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358275849 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358275849 | ||
| 003 | DE-627 | ||
| 005 | 20231226074408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/S0266462323000375 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358275849 | ||
| 035 | |a (NLM)37325997 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hogervorst, Milou Amber |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Uncertainty management in regulatory and health technology assessment decision-making on drugs |b guidance of the HTAi-DIA Working Group |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2023 | ||
| 500 | |a Date Revised 06.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface | ||
| 520 | |a METHODS: Six online discussions among WG members (Dec 2021-Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions | ||
| 520 | |a RESULTS: The WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: "unavailable," "inaccurate," "conflicting," "not understandable," "random variation," "information," "prediction," "impact," "risk," "relevance," "context," and "judgment." These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed | ||
| 520 | |a CONCLUSIONS: The systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a drugs | |
| 650 | 4 | |a health technology assessment | |
| 650 | 4 | |a regulatory decision making | |
| 650 | 4 | |a stakeholder deliberation | |
| 650 | 4 | |a uncertainty | |
| 700 | 1 | |a Vreman, Rick |e verfasserin |4 aut | |
| 700 | 1 | |a Heikkinen, Inkatuuli |e verfasserin |4 aut | |
| 700 | 1 | |a Bagchi, Indranil |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez-Ibarluzea, Inaki |e verfasserin |4 aut | |
| 700 | 1 | |a Ryll, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Eichler, Hans-Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Petelos, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Tunis, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Sapede, Claudine |e verfasserin |4 aut | |
| 700 | 1 | |a Goettsch, Wim |e verfasserin |4 aut | |
| 700 | 1 | |a Janssens, Rosanne |e verfasserin |4 aut | |
| 700 | 1 | |a Huys, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Barbier, Liese |e verfasserin |4 aut | |
| 700 | 1 | |a DeJean, Deirdre |e verfasserin |4 aut | |
| 700 | 1 | |a Strammiello, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Lingri, Dimitra |e verfasserin |4 aut | |
| 700 | 1 | |a Goodall, Melinda |e verfasserin |4 aut | |
| 700 | 1 | |a Papadaki, Magdalini |e verfasserin |4 aut | |
| 700 | 1 | |a Toussi, Massoud |e verfasserin |4 aut | |
| 700 | 1 | |a Voulgaraki, Despina |e verfasserin |4 aut | |
| 700 | 1 | |a Mitan, Ania |e verfasserin |4 aut | |
| 700 | 1 | |a Oortwijn, Wija |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of technology assessment in health care |d 1985 |g 39(2023), 1 vom: 16. Juni, Seite e40 |w (DE-627)NLM013402048 |x 1471-6348 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:1 |g day:16 |g month:06 |g pages:e40 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/S0266462323000375 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 1 |b 16 |c 06 |h e40 | ||